Classical Hodgkin Lymphoma - Histology

Relevant Publications

Hodgkin lymphoma and liquid biopsy: a story to be told.

Issue Release: 2024

The biology of classical Hodgkin lymphoma.

Issue Release: 2024

Two Cases of Synchronous Hodgkin Lymphoma and Papillary Thyroid Carcinoma in 18F-FDG PET/CT.

Issue Release: 2024

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.

Issue Release: 2024

Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-Risk Classical Hodgkin Lymphoma.

Issue Release: 2024

Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy.

Issue Release: 2024

Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis.

Issue Release: 2024

Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma.

Issue Release: 2024

Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen.

Issue Release: 2024

High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies.

Issue Release: 2024

Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv. 2023;7(20):6266-6274.

Issue Release: 2024

Epstein-Barr Virus Promotes Tumorigenicity and Worsens Hodgkin Lymphoma Prognosis by Activating JAK/STAT and NF-κB Signaling Pathways.

Issue Release: 2024

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial.

Issue Release: 2024

Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report.

Issue Release: 2024

Expression Patterns of GATA3 in Classical Hodgkin Lymphoma: A Clinico-Pathological Study.

Issue Release: 2024

Pinpointing Functionally Relevant miRNAs in Classical Hodgkin Lymphoma Pathogenesis.

Issue Release: 2024

T-cell States, Repertoire, and Function in Classical Hodgkin Lymphoma Revealed through Single-Cell Analyses.

Issue Release: 2024

Texture analysis of 18F-FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement.

Issue Release: 2024

The impact of treatment for childhood classical Hodgkin lymphoma according to the EuroNet-PHL-C2 protocol on serum anti-Müllerian Hormone.

Issue Release: 2024

Enhancing the treatment landscape: PET-guided BrECADD for advanced-stage, classical Hodgkin lymphoma.

Issue Release: 2024

How Can the N/C Ratio be Altered?

How is Histology Relevant to Adaptive Therapy?

What Happens When DDR Fails?

What Does the Curriculum Typically Include?

How Do Histologists Navigate Tissue Samples?

How Do Histologists Ensure High-Quality Images?

What is TNF Alpha?

What is Muscle Fiber Necrosis?

Why is sample size important in Histology?

How are Microneedles Made?

Partnered Content Networks

Relevant Topics